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Background: Moisturisers prevent and treat dry skin. They can also protect sensitive skin, improve skin tone and
texture, and mask imperfections. Herbal medicines or their extracts have been available as topical formulations and
cosmetics. Arctium lappa L. (Asteraceae) has been used to treat inflammatory disorders and various skin problems.
It could be a candidate herbal medicine for treating dry skin condition.
This study aims to establish the efficacy and safety of a proposed herbal moisturising cream containing Arctium
lappa L. seed extract, which has been approved by the Korean Ministry of Food and Drug Safety for use in
cosmetics.
Methods/Designs: This study is a randomised, double-blind, placebo-controlled study with two parallel groups
(proposed herbal moisturising cream vs. placebo cream). We will recruit 66 healthy male and female participants,
aged 20 to 65 years, who have been diagnosed with dry skin conditions. Participants will be randomly allocated to
receive either the proposed herbal moisturising cream or a placebo cream for four weeks. Each participant will be
examined for signs and symptoms before and after using the cream. Skin hydration, sebum (oily secretion) levels
and transepidermal water loss (TEWL; constitutive loss of water from the skin surface) will be assessed. Participants
will also be asked to fill out a health-related quality of life questionnaire. Safety will be assessed using blood tests,
urine analysis, a pregnancy test, and the assessment of vital signs.
Discussion: This trial will utilise high-quality methodologies in accordance with both consolidated standards for
reporting trials guidelines and the guidelines for clinical trials of cosmetics products that are aimed at expressions
and advertisement approval in Korea. It will evaluate the clinical efficacy and safety of a proposed herbal moisturising
cream containing Arctium lappa L. seed extract to treat dry skin conditions and provide itch relief. Moreover, we will
also employ health-related quality of life questionnaires to assess changes in the quality of life. The results of this study
will be used to present the evidence needed to request advertising/display allowances, in compliance with the recently
amended Cosmetics Act for advertisement in Korea.
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Dry skin is usually described as a rough, scaly and flaky
surface, which worsens under low humidity conditions
and often includes sensations of the loss of elasticity and
itch [1]. The causes of dry skin are still not fully under-
stood, and a characterisation and definition of this skin
disorder have only recently been completed [2,3]. It is
also known as a skin-barrier defect and is mainly attrib-
uted to a reduction in sebum secretion and consequent
loss of water from the stratum corneum (SC). A healthy
SC forms an effective permeability barrier that restricts
water loss from the body and blocks the penetration of
harmful irritants and allergens [4].
Moisturisers are commonly used by both patients with
dry skin conditions and people with healthy skin. How-
ever, a lack of knowledge persists regarding the effects of
moisturisers on skin barrier function [5]. Early studies
conducted on individuals with both healthy and diseased
skin showed that some moisturisers tend to weaken the
skin barrier function, whereas others may strengthen it,
and these discrepant results were assumed to be caused
by the varied compositions of moisturisers [5].
Complementary and alternative medicine (CAM) has
become increasingly popular among skin disease pa-
tients. A 2009 national survey study found that 49.4% of
patients with a skin problem in the United States had
used a CAM treatment within the previous year, and 6%
had used one of these treatments specifically for their
skin disease [6]. Several herbal medicines have been
promoted for ameliorating various dermatological con-
ditions, and some of them, such as propolis, rosemary, sage,
sumac and other extracts, are available in topical formula-
tions and cosmetics [7].
Arctium lappa L. (Asteraceae), which is commonly
known as burdock, has been popularly used to treat in-
flammatory disorders and various skin problems and
could be a candidate herbal remedy for dry skin condi-
tions [8]. Experimental studies have been conducted to
find the active ingredients responsible for increasing the
blood circulation to the skin surface, improving the skin
quality/texture and curing skin diseases [9]. However, to
our knowledge, the clinical trial of a moisturiser contai-
ning Arctium lappa L. has not yet been conducted.
Recently, regulations on cosmetics were heavily revised
to ensure safety in South Korea. Especially in terms of
advertising, only cosmetics products that have estab-
lished evidence using clinical trials are allowed to mark
and announce their efficacy. Moreover, according to le-
gislation by the Korean Ministry of Food and Drug
Safety (KMFDS), moisturisers cannot be recommended
for the treatment of skin diseases [10].
The purpose of this study is to establish the basic clin-
ical efficacy and safety of a proposed herbal moisturiser
cream containing Arctium lappa L. seed extract in healthypeople with dry skin conditions. This trial was designed
in accordance with the consolidated standards of re-
porting trials guidelines (CONSORT) and the guidelines
for clinical trials of cosmetics products that are aimed at
expression and advertisement approval in Korea [11]
and will be conducted as a randomised, double-blind,
placebo-controlled trial.
Methods/Design
A randomised, double-blind, placebo-controlled trial will
be conducted at the Wonkwang University Oriental
Medical Centre in Gunpo, Korea. Participants fulfilling
the eligibility criteria will be selected. Enrolled partici-
pants will be randomly allocated to one of two parallel
groups: the proposed herbal moisturising cream or the
placebo cream. Each participant will be examined for
signs and symptoms of skin conditions before and after
taking the medication. A follow-up to evaluate the long-
term safety will be performed via a phone call (Figure 1).
Recruitment
We will recruit participants by advertising in local medical
centres and on the websites of local medical centres of
Gyeonggi province. Respondents will be contacted by cli-
nical trial coordinators (CRC) to determine eligibility via a
telephone pre-screen. If an applicant meets the study cri-
teria, he or she will be invited to the clinical research cen-
tres to be further examined for eligibility. Korean medicine
doctors and internal medicine doctors will conduct the
screening together to improve the quality of the eligibility
assessment. Korean medicine doctors will manage the
screening process. Internal medicine doctors will assess
the complete blood cell count (CBC), erythrocyte sedi-
mentation rate (ESR), blood chemistry, urine analysis, and
vital signs to exclude patients with serious liver and kidney
diseases. Following a pregnancy test, pregnant women will
be excluded from the clinical trials.
Inclusion criteria
Eligible participants of both sexes who are 20 to 65 years
of age will be enrolled according to the inclusion and ex-
clusion criteria. We will include participants who present
itching or dry skin conditions. The diagnosis of a dry skin
condition will be made by the doctor (Korean medicine).
Healthy volunteers without skin diseases or any other dis-
eases (acute or chronic) will be enrolled. Participants will
be instructed regarding their participation during the run-
in, treatment, and follow-up periods. Written informed
consent will be obtained from each participant.
Exclusion criteria
Participants will be excluded if they suffer from any serious
medical conditions, such as uncontrolled hypertension, dia-
betes mellitus requiring insulin injection, past or current
Group A (n=33)
Proposed herbal  
moisturising cream
Patient recruitment
Screening of Patients by Eligibility Criteria




Application for 2 weeks (1st)
Outcome Assessment 2 weeks after the first moisturiser application 
Application for 2 weeks (2nd)
Outcome Assessment 4 weeks after the first moisturiser application 
Follow-up (2 weeks after treatment discontinuation)
Figure 1 Study flow chart.
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pulmonary tuberculosis, other severe dermatitis, or any in-
fectious or systemic diseases. The exclusion criteria are as
follows: pregnancy, lactation, or planned pregnancy; use of
a topical medication containing steroids for the treatment
of skin disease more than once per month; participation in
the same trial within six months from the interview; hyper-
sensitive skin; skin abnormalities, such as severe acne, ery-
thema, or telangiectasia at the test site; use of the same or
similar cosmetics (or pharmaceutical) on the test site within
three months of the interview; having undergone a skinpeeling or having wrinkles removed within six months of
the interview; and any other reasons of unsuitability for the
clinical trial at the discretion of the investigator.
Exclusion will be primarily based on information pro-
vided by the patients. In addition, additional examinations,
such as CBC, ESR, blood chemistry, urine analysis, a preg-
nancy test, and the assessment of vital signs will be per-
formed before the trial to ensure that the patients do not
suffer from any diseases.
We will record the drugs taken by each participant at
every visit, and the participants will be asked to notify us
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men. The complete eligibility criteria are provided in
Appendix 1.
Sample size
We wish to estimate the sample size necessary to detect
significant differences in skin hydration measured using a
Corneometer® 825 (Courage and Khazake, Electronic
GmbH, Colongne, Germany) [12], between the experi-
mental and control groups. Sample size was determined
based on the results of a recent study [13] in which the
mean difference and standard deviation of both groups
were 0.94 and 1.22, respectively. The following formula
was used to estimate the sample size for a two-group trial:




Calculations were performed using 80% power, a 5%
significance level, and a 20% dropout rate. The required
sample size was approximately 27 participants for each
group. We plan to enrol 33 participants in each of the
two groups to allow for a 20% withdrawal rate, which
will ensure that the sample size is in excess of 20, in ac-
cordance with the clinical research guidelines of the
KMFDS.
Randomisation and allocation
The randomisation procedure will be guaranteed by
Coreana, a consignment organisation. A statistics expert
who will have no contact with the study participants will
conduct the randomisation of the participants. Partici-
pants will be assigned random numbers using a random
number generator program (Microsoft Office Excel 2007).
These random numbers will be sent to the clinical centre,
and the randomisation table will be kept blind by the
consignment organisation during the research period.
Ultimately, 66 participants will be randomised into two
groups. Opaque-sealed envelopes containing serial num-
bers will be delivered to the clinical centre. An opaque-
sealed randomisation table kept by the consignment
organisation should be opened as part of the Standard
Operating Procedure (SOP). If it has to be opened during
an urgent situation involving serious adverse events, the
primary investigator must report the incident to the Ethics
Committee and the consignment organisation. Before the
random assignment, all participants will be informed that
they will be assigned to one of two groups. Random allo-
cation will be conducted during the second visit. Random
numbers will be matched to their corresponding partici-
pants according to the order of the time of second visit.
The group assignment results will not be announced to
the participants until the last visit of the last participant.Blinding
During the trial, investigators will not be in contact with
the consignment organisation, the clinical pharmacist, or
the statistician. The success of the blinding will be
assessed at the last visit of each participant. Researchers
who are blinded to the group assignment results will per-
form the outcome assessment. The blinding procedure
will also be verified by the consignment organisation.
Treatment protocol
Participants will receive the proposed herbal moisturis-
ing cream or a placebo cream for four weeks. Applica-
tion occurs according to the following directions:
Patients in group 1 will receive proposed herbal moist-
urising cream and instructions on how to apply; they
should use an entire packet of the cream (2.00 g) daily.
The cream should be applied to the affected areas of
skin, to the inner surface of left forearm and to the right
side of the face after washing, twice daily (morning and
evening), for four weeks.
Patients in group 2 will receive the placebo cream with
the same instructions that were provided to group 1.
The defined daily doses (DDDs) of these moisturising
creams should be determined based on the specifications
and analytical procedures of drug products provided in
the KMFDS guidelines. However, no pilot study has pre-
viously been reported.
Experimental cream
Coreana Cosmetics Co. Ltd. produced the proposed
herbal moisturising cream and the placebo cream ac-
cording to Korea Good Manufacturing Practice (KGMP)
standards.
The proposed herbal moisturiser used in this trial is a
white, cream-type moisturiser. The proposed herbal
moisturising cream is composed of three active ingredi-
ents: a controller of sebum biosynthesis; a 70% ethanol
extract from the seeds of Arctium lappa L.; and vernix
caseosa matrix.
Placebo cream
Coreana Cosmetics Co. Ltd. developed a homogenous
cream that is composed of a base approved by the
KMFDS. The colour, form, weight, and scent of the pla-
cebo are similar to those of the treatment cream.
Primary outcome measurement
Skin hydration (Corneometer®), sebum levels (Sebumeter®)
and TEWL (Tewameter®) will be assessed as the primary
outcome measurements. These parameters will be mea-
sured on day 1, day 15 and day 29.
Skin hydration (Corneometer®) will be measured three
times at the affected areas of skin, on the inner surface
of the left forearm and on right side of the face after
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analysis.
Sebum levels (Sebumeter®) will be measured at the af-
fected areas of skin and on the surfaces of the forehead,
cheeks and chin after washing and cleansing (with 70%
ethanol). After 60 minutes, the same areas will be mea-
sured again, and the differences between two numerical
values will be calculated.
After washing, the TEWL (Tewameter®) will be mea-
sured three times at the affected areas of skin, on the
inner surface of the left forearm and on the right side of
the face for 30–50 seconds, and the mean values will be
adapted for the analysis.
Secondary outcomes
Secondary outcome measurements include the SC mois-
ture levels (Corneofix®), visual analogue scale (VAS)-xero-
sis, and VAS-itching. These parameters will be measured
on days 1, 15 and 29. The EuroQoL 5-Dimension (EQ-
5D), the Health Utilities Index Mark 3 (HUI3), and the
Dermatology Life Quality Index (DLQI) will be admi-
nistered on day 1 and day 29 as measures of the health
outcomes. The data collection schedule is detailed in
Table 1.
Patient safety
All patients will undergo routine testing that includes the
following assays: CBC, ESR, blood chemistry, pregnancy
test, and urine analysis before randomisation and imme-
diately after completing the treatment. Vital signs will beTable 1 Data collection schedule
Period Screening Treatment period Follow-up
Visit
1st 2nd 3rd 4th






Safety assessment ○ ○ ○ ○
Skin hydration ○ ○ ○












Adverse effects ○ ○ ○
Blinding assessment ○measured at every visit. These tests help identify and ex-
clude patients with serious liver and kidney disease or
other severe illness. Investigators will assess a significant
result in these tests according to explicit criteria defining
the incidence and intensity of adverse events. In addition,
pictures of the skin lesions will be recorded as a means of
evaluating the adverse events.
Statistical analysis
Analyses will be performed for two populations: 1) an
intention-to-treat population consisting of all randomised
participants who have at least one measurable outcome
report following treatment (missing data are replaced with
the last observed values) and 2) a per-protocol population
including only participants without any major protocol
deviations. All baseline characteristics of both groups will
be described. All of the main analyses will be based on the
intention-to-treat population and conducted using the
LOCF (last observation carried forward) imputation
method. For primary outcome measures, the mean differ-
ence from baseline values at the end of treatment will be
compared using independent t-tests (expected noncentral-
ity parameter = 2.90, critical t = 2.00, power = 0.80). Paired
t-tests or non-centrality Wilcoxon rank sum tests will
be used to compare the safety variables. Repeated mea-
sures ANOVA (analysis of variance) or repeated measures
ANCOVA (analysis of covariance) tests will also be per-
formed as within-group and between-group analyses.
Baseline data will be collected on each participant du-
ring the randomisation and can be used to describe
the population of patients, to compare the treatment
groups, to achieve balance in the randomisation, to ad-
just for possible confounding of the prognostic factors,
and to undertake subgroup analyses. We will exercise
caution when drawing conclusions from the subgroup
findings.
Statistical analyses will be performed using the STATA
statistical package program (ver. 11.2), and the level of
significance will be established at α = 0.05.
Data and safety monitoring
To maintain the quality of this trial, monitoring will be
conducted by Coreana, a consignment organisation that
is located in Chungnam, Korea. Investigators can also
convene to discuss practical issues that they might en-
counter, such as dealing with serious adverse events, revi-
sing the protocol, and addressing certain important issues
that might be raised by investigators and participants. We
define adverse events as unintended signs, symptoms, or
diseases occurring after treatment that may or may not
be related to the intervention. The safety assessment is
based primarily on the frequency of adverse events, in-
cluding all serious adverse events. Information on the
adverse events will be summarised by presenting the
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any adverse events. During the trial, all adverse events
will be observed in detail and documented using case
report forms (CRFs).
Ethics
Written consent will be obtained from each participant.
This study protocol was approved by the institutional re-
view board (IRB) of the Wonkwang University Oriental
Medical Centre.
Discussion
Dry skin is a common symptom of a number of skin dis-
eases, including atopic dermatitis/eczema, ichthyosis, irri-
tant contact dermatitis, psoriasis and asteatotic eczema,
and can also be seen in healthy individuals [1,14]. It is
more prevalent in geriatric populations than in younger
patients and could be affected by environmental factors,
such as frequent washing, the use of harsh detergents and
exposure to low-humidity air [4]. These factors can influ-
ence moisturiser studies, and so in this study, certain clin-
ical and habitual factors, such as the menopausal state,
bathing habits and the treatment experiences of other skin
diseases will be included in the baseline assessments.
Prior studies of moisturisers have mainly focused on
short-term results using measurement devices, as it is pos-
sible to attain an improvement in the skin moisture
shortly after a single application. Nevertheless, long-term
studies are important to assess the maintenance and en-
hancement of this effect [15], and we designed a 6 week
study period for observing the long-term results.
Although dry skin is not a life-threatening condition,
the symptom is apparently unpleasant and can lead to
deterioration in the quality of life [14], which should also
be considered during moisturiser studies. Therefore, in
addition to the primary outcome and secondary out-
comes that were measured using instruments, the EQ-
5D, HUI-III, DLQI self-reported measures were also
included to examine changes in the general and disease-
specific quality of life.
Herbal products have gained increasing popularity and
are now used by approximately 20% of the population in
the United States [16]. Similar usage patterns can be ob-
served for cosmetics, and due to the harmful effects of
chemicals, studies and markets have focused on herbal
cosmetics [17]. The South Korean cosmetics report re-
vealed that sales of herbal cosmetics had expanded more
than 2 fold over the last 5 years, accounting for 23.5% of
the total cosmetics market in 2010 [18]. In this context,
various herbal medicines, such as A. lappa, have been
studied as potential cosmetics products. A recent expe-
rimental study reported that an A. lappa fruit extract-
containing formulation improved the metabolism of the
dermal extracellular matrix and lead to a visible reductionin wrinkles [19]. However, side effects have also been re-
ported for A. lappa, such as contact dermatitis [20] and
anaphylaxis [21]. Therefore, the potential for rare but
dangerous side effects indicate that safety issues should
also be examined during clinical trials. In this study, we
will perform blood tests, urine analysis and adverse
event case reports to confirm the safety of the proposed
herbal moisturiser.
In conclusion, the present trial includes two unique fea-
tures. First, we developed a protocol in conjunction with
the recommendations of the consolidated standards of
reporting trials (CONSORT) checklists for herbal inter-
ventions and the clinical trial guidelines of the KMFDS for
cosmetics products. Second, we conducted a systematic
review before developing the study design and adopted
outcome measurements following the results [22].
This study will demonstrate the efficacy and safety of
the proposed herbal moisturiser in healthy people with
dry skin conditions.
Appendix 1: Eligibility Criteria
Inclusion criteria
1. Volunteer individuals aged 20 to 65 years, either sex.
2. Written and informed consent.
3. Healthy volunteers without skin disease or any
other diseases (acute or chronic).
4. Diagnosed with dry skin by the doctor (Korean
medicine) or presenting with itching or a dry skin
condition.
5. Available for follow-up observations during the
clinical trial period.
Exclusion criteria
1. Pregnancy, lactation, or planned pregnancy.
2. The use of a topical medication containing steroids
to treat skin disease more than once a month.
3. Participation in the same trial within six months of
the interview.
4. Hypersensitive skin.
5. Skin abnormalities, such as severe acne, erythema,
or telangiectasia at the test site.
6. Use of the same or similar cosmetics (or
pharmaceuticals) at the test site within three months
of the interview.
7. Having undergone a skin peeling or wrinkle
removal procedure during the six months prior to
the interview.
8. Any other reasons of unsuitability for the clinical
trial at the discretion of the investigator.
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